The Strategic Advantage of U.S. Manufacturing for Nicotine Free Solutions

The Strategic Advantage of U.S. Manufacturing for Nicotine Free Solutions

In recent decades, the United States has become increasingly dependent on foreign manufacturing for the medicines and healthcare products consumed by its own population. Today, it is widely estimated that approximately 80 percent of the active pharmaceutical ingredients used in drugs taken by Americans are manufactured outside the United States.³ At the same time, the U.S. Food and Drug Administration reports that “about 72 percent of establishments manufacturing active pharmaceutical ingredients for U.S. marketed drugs are located outside of the United States.”¹

This reality has raised growing concerns among policymakers, regulators, and healthcare experts. When the majority of the core components used to manufacture medicines originate abroad, it creates potential vulnerabilities in supply chains that millions of patients rely upon every day.

The U.S. Government Accountability Office has warned that the federal government “lacks complete information on the extent to which U.S. marketed drugs rely on foreign manufactured active pharmaceutical ingredients.”² In practical terms, this means that regulators and policymakers do not always have full visibility into where the underlying chemical components of critical medications originate or how dependent the U.S. healthcare system may be on foreign production.

These concerns have intensified in recent years as global supply chains have experienced disruptions. During the COVID-19 pandemic, manufacturing shutdowns, transportation delays, and export restrictions demonstrated how quickly international supply chains can become unstable. The Government Accountability Office noted that these disruptions “exposed vulnerabilities in the U.S. pharmaceutical supply chain.”²

For healthcare technologies that may one day support millions of people, manufacturing location is therefore more than a business decision. It is increasingly viewed as a matter of supply chain resilience, regulatory transparency, and national healthcare security.

For this reason, many healthcare innovators are reexamining the role of domestic manufacturing.

Redwood Scientific Technologies has taken the position that rebuilding advanced healthcare manufacturing capacity within the United States represents an important long term objective. Rather than relying on complex overseas supply chains, the company’s strategy focuses on building technologies that can be produced within the United States under strict regulatory and quality oversight.

Manufacturing within the United States allows companies to operate within one of the most rigorous regulatory environments in the world. Facilities must comply with strict manufacturing standards, quality control protocols, and regulatory oversight designed to ensure consistency and safety in healthcare related products.¹

Domestic manufacturing also allows companies to maintain closer supervision over production processes. Research teams, manufacturing leadership, and quality control specialists can operate within the same regulatory framework and geographic environment, allowing for faster adjustments, improved transparency, and stronger oversight.

For investors evaluating emerging healthcare technologies, manufacturing strategy has therefore become an increasingly important consideration. Companies that maintain greater control over their production infrastructure may be better positioned to manage regulatory compliance, protect intellectual property, and scale production as demand increases.

Beyond where a product is manufactured, the format in which it is delivered can also play a critical role in its effectiveness and accessibility.

One delivery technology that has gained increasing attention across the healthcare sector is oral thin film delivery.

Oral thin film technology involves dissolvable strips designed to dissolve in the mouth and deliver compounds through oral absorption. These strips are lightweight, portable, and require no water or preparation before use. Research published through the National Institutes of Health describes oral thin films as offering “rapid dissolution, improved convenience, and enhanced patient compliance.”⁴

For individuals attempting to change deeply ingrained habits such as smoking or vaping, convenience can be an important factor. Products that are simple to carry and easy to use may integrate more naturally into daily routines.

This delivery technology forms the platform behind Redwood Scientific Technologies’ TBX FREE and TBX VAPE FREE systems. These products are designed using oral thin film technology and focus on nicotine free approaches intended to support individuals seeking to transition away from cigarettes and vaping products.

Unlike many traditional cessation tools that rely on nicotine replacement therapies, Redwood’s technology focuses on nicotine free formulations designed to address behavioral patterns associated with smoking and vaping.

The scale of the smoking challenge remains significant. The World Health Organization reports that tobacco use “kills more than 8 million people each year worldwide.”⁵ Public health organizations estimate that more than one billion people worldwide continue to smoke cigarettes.⁵

These realities continue to drive demand for new technologies designed to support smoking and vaping cessation. Governments, healthcare providers, and regulators are increasingly focused on helping individuals transition away from nicotine based products.

In this evolving landscape, companies that combine innovative product platforms with reliable manufacturing infrastructure may be well positioned to contribute to the next generation of smoking cessation solutions.

Manufacturing strategy, delivery technology, and scientific research are all part of the broader equation. As the global transition away from smoking continues, these factors may increasingly shape which companies lead the development of new solutions designed to address one of the most persistent public health challenges in modern history.

 

Sources and References

1. U.S. Food and Drug Administration
   “About 72 percent of establishments manufacturing active pharmaceutical ingredients for U.S. marketed drugs are located outside of the United States.”
   https://www.fda.gov
2. U.S. Government Accountability Office
   “The federal government lacks complete information on the extent to which U.S. marketed drugs rely on foreign manufactured active pharmaceutical ingredients.”
   https://www.gao.gov
3. Congressional Research Service
   Approximately 80 percent of active pharmaceutical ingredients used in medicines consumed in the United States are manufactured overseas.
   https://crsreports.congress.gov
4. National Institutes of Health
   Oral thin films offer “rapid dissolution, improved convenience, and enhanced patient compliance.”
   https://www.ncbi.nlm.nih.gov
5. World Health Organization
   “Tobacco kills more than 8 million people each year worldwide.”
   https://www.who.int/news-room/fact-sheets/detail/tobacco

 

About Redwood Scientific Technologies, Inc.
Redwood Scientific Technologies, Inc. is focused on developing innovative nicotine free technologies designed to help smokers transition away from combustible cigarettes and nicotine based products. The company’s TBX FREE and TBX VAPE FREE platforms are designed to address the behavioral and sensory aspects of smoking cessation while eliminating nicotine.
Redwood has previously achieved large scale commercial distribution of its oral thin film technologies and continues to advance new solutions designed for the global smoking cessation market. With more than 1 billion smokers worldwide and increasing regulatory pressure on both cigarettes and vaping products, demand for effective nicotine free alternatives continues to grow.
Additional information about Redwood Scientific Technologies can be found at
https://redwoodsci.com

Additional Company Disclosure
Redwood Scientific Technologies, Inc. is currently advancing the development of its nicotine free cessation technologies, including TBX FREE and TBX VAPE FREE. The company is in the process of completing required clinical validation through controlled research protocols.
Redwood’s products are not currently being marketed or sold. The company intends to complete a double blind placebo controlled efficacy study covering both product platforms prior to any commercial launch. These studies are designed to evaluate the effectiveness of the products in supporting smoking and vaping cessation and to provide data suitable for scientific publication.
Until those studies are completed and the company finalizes its clinical and regulatory strategy, Redwood Scientific Technologies does not offer these products for sale.
In addition, Redwood’s commercial strategy is structured as a business to business distribution model. The company does not sell products directly to end users or directly to consumers. Instead, Redwood intends to work through licensed distributors, healthcare partners, and institutional channels for future product distribution.
Forward Looking Statement Notice
Certain statements contained in this article constitute forward looking statements within the meaning of applicable securities laws. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Forward looking statements include, but are not limited to, statements regarding clinical studies, product development, regulatory strategy, commercialization plans, and market opportunities.
Readers and investors should not place undue reliance on forward looking statements, which speak only as of the date of publication.
This article is provided for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities.